Anika Therapeutics, Inc. (ANIK): who owns it and who trades it
As of Nov 16, 2026, ANIK insiders reported 4 purchases worth $264K in the last 12 months. The largest buyer was Stephen D. Griffin (CEO), with $150K. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Anika Therapeutics
From the latest filingsOverall: more buying than selling. Insiders and famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ANIK
132 funds and institutions reported ANIK shares worth $182M at the end of Q2 2026, about 93% of the company. The largest holder is BlackRock, Inc. with 10.9%.
Funds and institutions (13F) 93%Everyone else 7%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 1.45M | 10.90% | $21.2M | -9% |
| Caligan Partners LP | 1.44M | 10.79% | $21M | No change |
| Morgan Stanley | 614,320 | 4.62% | $9M | -30% |
| Acadian Asset Management LLC | 606,544 | 4.56% | $8.9M | No change |
| Vanguard Capital Management LLC | 572,113 | 4.30% | $8.4M | -6% |
| AQR Capital Management LLC | 559,846 | 4.21% | $8.2M | +106% |
| Boothbay Fund Management, LLC | 529,640 | 3.98% | $7.7M | No change |
| Renaissance Technologies LLC | 481,417 | 3.62% | $7M | -4% |
| Dimensional Fund Advisors LP | 451,095 | 3.39% | $6.6M | -2% |
| Capital Management Corp | 448,474 | 3.37% | $6.6M | +0% |
| Deutsche Bank Ag\ | 353,552 | 2.66% | $5.2M | +0% |
| Geode Capital Management, LLC | 331,577 | 2.49% | $4.9M | +0% |
| State Street Corp | 311,896 | 2.34% | $4.6M | -10% |
| Two Sigma Investments, LP | 252,964 | 1.90% | $3.7M | +7% |
| D. E. Shaw & Co., Inc. | 245,066 | 1.84% | $3.6M | +7% |
| Goldman Sachs Group Inc | 237,722 | 1.79% | $3.5M | +9% |
| Jacobs Levy Equity Management, Inc | 217,530 | 1.63% | $3.2M | -18% |
| Nuveen, LLC | 156,538 | 1.18% | $2.3M | +30% |
| Quantinno Capital Management LP | 155,257 | 1.17% | $2.3M | +23% |
| UBS Group AG | 145,816 | 1.10% | $2.1M | +10% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ANIK insiders reported $264K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026 | Gary P Fischetti | Director | Purchase | 1,000 | $20.32 | $20.3K | Form 4 |
| Aug 3, 2026 | Gary P Fischetti | Director | Purchase | 1,000 | $20.75 | $20.8K | Form 4 |
| May 1, 2026 | John B Henneman III | Director | Purchase | 5,000 | $14.66 | $73.3K | Form 4 |
| Apr 30, 2026 | Stephen D. Griffin | CEO | Purchase | 12,200 | $12.29 | $150K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Stephen D. Griffin | President and CEO, Director | $150K | – | Apr 30, 2026 |
| John B Henneman III | Director | $73.3K | – | May 1, 2026 |
| Gary P Fischetti | Director | $41.1K | – | Aug 4, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ANIK short interest
Low short interest. 2.4% of ANIK shares are sold short: about 1 share in 41. Over the last 12 reports the number of shares short went down 43%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 323,508 ANIK shares were sold short, 2.4% of the shares outstanding, down 11.5% from the report before. At the average daily volume of 103,489 shares, buying them all back would take about 3.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 323,508 | 2.42% | -12% | 103,489 | 3.1 |
| Oct 15, 2026 | 365,717 | 2.73% | -0% | 109,203 | 3.4 |
| Sep 30, 2026 | 367,155 | 2.74% | -4% | 83,024 | 4.4 |
| Sep 15, 2026 | 381,376 | 2.85% | +10% | 71,095 | 5.4 |
| Aug 31, 2026 | 345,448 | 2.58% | +2% | 127,914 | 2.7 |
| Aug 14, 2026 | 337,211 | 2.52% | +10% | 148,401 | 2.3 |
| Jul 31, 2026 | 307,573 | 2.30% | -12% | 70,850 | 4.3 |
| Jul 15, 2026 | 349,776 | 2.63% | -16% | 75,418 | 4.6 |
| Jun 30, 2026 | 416,970 | 3.13% | -2% | 85,260 | 4.9 |
| Jun 15, 2026 | 425,011 | 3.19% | -25% | 60,214 | 7.1 |
| May 29, 2026 | 562,976 | 4.23% | -0% | 71,570 | 7.9 |
| May 15, 2026 | 565,572 | 4.25% | +2% | 104,518 | 5.4 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Anika Therapeutics company events
Anika Therapeutics filed 7 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 6, 2026.
- Nov 6, 2026ResultsReleased financial results. Filing
- Jul 29, 2026ResultsReleased financial results. Filing
- Jul 14, 2026AgreementWe entered into a Fifth Amendment to Credit Agreement, or the Fifth Amendment, amending our existing revolving line of credit agreement dated October 24, 2017 with Bank of America, N.A., which revolving line of credit agreement, as amended to date (including by such Fifth Amendment), we refer to as… Filing
- Jun 23, 2026LeadershipThe board of directors, or the Board, of Anika Therapeutics, Inc., or the Company, adopted and approved, subject to stockholder approval, a sixth amendment and restatement of the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan as previously amended, or the 2017 Plan, and on June 8, 2026, the… Filing
- Apr 29, 2026LeadershipBoth William R. Jellison, a Class I member of the Board of Directors of the Company, and Glenn R. Larsen, Ph.D., a Class II member of the Board, notified the Board of their resignation from the Board, including from all committees on which each serves effective as of the Company’s 2026 annual… Filing
- Feb 26, 2026LeadershipThe Company and Mr. Colleran entered into a Transitional Services and General Release of Claims Agreement. Filing
- Jan 8, 2026LeadershipThe Company announced that, effective February 1, 2026, Cheryl R. Blanchard will transition from her role as President and Chief Executive Officer. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Anika Therapeutics financials
Famous investors that hold ANIK
5 of the 50 well-known investors we track reported holding ANIK in their latest 13F filing. The largest position is Jim Simons's, worth $9M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 458,717 | $9M | 0.0% | -5% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 33,683 | $662K | 0.0% | +47% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 23,139 | $455K | 0.0% | +3% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 21,792 | $428K | 0.0% | New |
| Israel Englander · Millennium Management | Q3 2026 | 17,210 | $338K | 0.0% | +19% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Anika Therapeutics, Inc. (ANIK) stock
Who owns the most ANIK stock?
The largest reported owner of Anika Therapeutics, Inc. (ANIK) is BlackRock, Inc., with 10.9% of the company. In total, 132 funds and institutions reported holding ANIK at the end of Q2 2026, together about 93% of the shares. See the largest owners.
Are ANIK insiders buying or selling?
In the last 12 months, ANIK insiders reported 4 open-market purchases worth $264K and no sales. The latest trade was on Aug 4, 2026. See every trade.
What is the short interest in ANIK?
As of Oct 30, 2026, 323,508 ANIK shares were sold short, 2.4% of the shares outstanding, down 11.5% from the report before. At the average daily volume of 103,489 shares, buying them all back would take about 3.1 trading days (days to cover). See the history.
Which famous investors hold ANIK?
5 of the 50 well-known investors we track reported ANIK in their latest 13F filing, including Jim Simons, Paul Tudor Jones, Steve Cohen. The largest position is worth $9M. See all holders.
Executive pay
Anika Therapeutics's chief executive was paid a total of $4.9M for the year ended Dec 31, 2025, down 4% from $5.1M the year before. In the last 12 months, Anika Therapeutics's executives and directors bought $264K of stock on the open market and sold none.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.